OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $284,000.00 in Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the sale, the insider now owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. This trade represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80.

OS Therapies Trading Down 11.7 %

OSTX opened at $1.97 on Wednesday. OS Therapies Inc has a 1-year low of $1.58 and a 1-year high of $7.00. The company has a 50 day simple moving average of $3.40 and a two-hundred day simple moving average of $3.16.

Analyst Ratings Changes

Several brokerages recently issued reports on OSTX. D. Boral Capital restated a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research report on Thursday, January 30th. Maxim Group boosted their target price on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC grew its position in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.